A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer

Conclusion: The combination of gemcitabine, erlotinib, and S-1 provided an acceptable toxicity profile and modest clinical benefits in patients with advanced pancreatic cancer.

Source: Journal of Cancer - January 15, 2021 Category: Cancer & Oncology Authors: Boram Han, Bum Jun Kim, Hyeong Su Kim, Dae Ro Choi, Byoung Yong Shim, Kyung Hee Lee, Jin Won Kim, Jung Han Kim, Hunho Song, Jong Hyeok Kim, Choong Kee Park, Jung Woo Lee, Min-Jeong Kim, Dae Young Zang Tags: Research Paper Source Type: research